Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine-based combination regimens versus standard care for hospitalized COVID-19
PACTR202010519682638Phase 3Not yet recruiting
- Sponsor
- National Institute for Pharmaceutical Research and Development
- Start
- Aug 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of hydroxychloroquine, lopinavir and ritonavir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by National Institute for Pharmaceutical Research and Development. Primary endpoints: Rate of virus inhibition and Time from randomization to recovery. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
hydroxychloroquinelopinavirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202010519682638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202010519682638.